Ocata Therapeutics Inc fka OCAT

[lasers]

For those that are Pharmaceutical Veterans with Science Degrees, it is very obvious that Lancet $OCAT TLD RPE Phase2A publication contains no results data on the better vision 20/100 patients. There had been more than ample time for such data to be available and yet none was given for the Lancet TLD public publication.

Such a Pharmaceutical Veteran with Science Degrees as Dr. Paul Wotton would have requested and thoroughly reviewed such info before making his dramatic decision to leave Antares and join $ACTC, now $OCAT. The results for the better vision 20/100 is absolutely key for the planned Phase2B Protocol agreement with the FDA and as well for the purchaser(s) of the new 10 mil shares, $62 mil.